Synthesis of Chitosan-based Captopril Derivatives and Its in vitro Release

被引：0
作者：
Li H. [1 ]
Xiao Q. [2 ]
Qin L. [1 ]
机构：
[1] School of Chemistry and Biological Engineering, Changsha University of Science and Technology, Changsha
[2] Department of Basic Education, Yunnan Water Resources and Hydropower Vocational College, Kunming
来源：
Li, Heping (lihp@csust.edu.cn) | 2018年 / Hunan University卷 / 45期
基金：
中国国家自然科学基金;
关键词：
Captopril; Chitosan; Slow-releasing; Synthesis;
D O I：
10.16339/j.cnki.hdxbzkb.2018.06.022
中图分类号：
O62 [有机化学]; TQ [化学工业];
学科分类号：
070303 ; 0817 ; 081704 ;
摘要：
In order to overcome the burst release of water-soluble drugs, reduce dosing frequency and improve curative effect,two new bond-linking type drug-loaded control-releasing systems: Chitosan-Captopril and Chitosan-Lysyl-Captopril were synthesized from captopril as a model drug and chitosan as carriers. The products were characterized by IR, 1H NMR and MS. The accumulation of drug release rates of Chitosan-Captopril are 59.2% in PBS buffer (pH=7.4) and 78.4% in HCl-KCl buffer (pH=1.2). The accumulation of drug release rates of Chitosan-Lysyl-Captopril are 55.2% in PBS buffer (pH=7.4) and 76.4% in HCl-KCl buffer (pH=1.2). The results show that the two kinds of drug-loaded systems eliminate the phenomenon of burst releasing and have excellent sustained release properties, which are expected to become the ideal control-releasing system of water-soluble drugs. © 2018, Editorial Department of Journal of Hunan University. All right reserved.
引用
收藏
页码：145 / 149
页数：4
相关论文
共 10 条
  • [1] Wang J.K., Gao L., Liu Y., Solubility of captopril in 2-propanol, aetone, aetonitrile, mhyl aetate, ehyl aetate, and btyl aetate, Journal of Chemical and Engineering Data, 55, pp. 966-967, (2010)
  • [2] Asiri A.M., Khan A.P., Khan A., Spectroscopic investigation on kinetics and mechanistic aspects to electron-transfer process into quinolinium dichromate oxidation of a high blood pressure drug captopril in acidic medium, Journal of Molecular Liquids, 203, pp. 1-6, (2015)
  • [3] Levy M., Koren G., Klein J., Et al., Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring, Development of Pharmacology Therapy, 4, pp. 185-193, (1991)
  • [4] Nur A.O., Zhang J.S., Recent progress in sustained: controlled oral delivery of captopril: an overview, International Journal of Pharmaceutics, 194, 2, pp. 139-146, (2000)
  • [5] Mandal A.S., Chatterjee S., Kundu S., Et al., In vitro-in vivo correlation and bioavailability studies of captopril from novel controlled release donut shaped tablet, International Journal of Pharmaceutics, 421, 1, pp. 145-150, (2011)
  • [6] Sauri J., Millan D., Sune-Negre J.M., Et al., Quality by dsign approach to understand the physicochemical phenomena involved in controlled release of captopril SR matrix tablets, International Journal of Pharmaceutics, 477, 1-2, pp. 431-441, (2014)
  • [7] Qu F., Zhu G., Huang S., Et al., Controlled release of cptopril by regulating the pore size and morphology of ordered mesoporous silica, Microporous and Mesoporous Materials, 92, pp. 1-9, (2006)
  • [8] Khlibsuwan R., Pongjanyakul T., Chitosan-clay matrix tablets for sustained-release drug delivery: Effect of chitosan molecular weight and lubricant, Journal of Drug Delivery Science and Technology, 35, pp. 303-313, (2016)
  • [9] Chen X.H., Xiong Y.N., Wang J., Et al., Preparation of chitosan/multi-walled carbon nanotubes membrane and its performance of methyl orange adsorption and Cu<sup>2+</sup> rejection, Journal of Hunan University(Natural Sciences), 42, 6, pp. 34-40, (2015)
  • [10] Aijala M., Santaniemi M., Bloigu R., Et al., Leptin receptor Arg109 homozygotes display decreased total mortality as well as lower incidence of cardiovascular disease and related death, Gene, 534, pp. 88-92, (2014)
1